Oncology companies are involved in the diagnosis or treatment of cancer through the production of pharmaceuticals, devices or serviced-based models. Based in Massachusetts, oncology startup Xilio Therapeutics develops tumor-selective immunotherapies to improve patient outcomes. More specifically, the company created a new class of ultra-potent immune-oncology (IO) therapies that are activated selectively within tumors and are designed to overcome the toxicities associated with validated IO therapies.
was successfully added to your cart.
